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A series of diamondoid-decorated organotin(IV) derivatives of composition Me3Sn(L1) (1), 
Ph3Sn(L1) (2), {[Me2Sn(L1)]2O}2 (3), [BzSn(O)(L1)]6 (4), Me3Sn(L2)OH2 (5), [Ph3Sn(L2)]n 
(6), Bu2Sn(L2)2 (7), Bz2Sn(L2)2OH2 (8) and [BzSn(O)(L2)]6 (9) were prepared by reacting 
appropriate organotin(IV) precursors with either acid forms of the pro-ligands adamantane-1-
carboxylic acid (HL1) and 2-(adamantan-1-yl)acetic acid (HL2) or their sodium salts. 
Compounds 1-9 were characterised by spectroscopic techniques, including 119Sn NMR in 
non-coordinating solvent for assessment of the solution-state structures. The molecular and 
crystal structures of 2-8 were established by X-ray crystallography. The packing is largely 
dictated by hydrophobic interactions with the exception in the crystals of 6, where Sn…O 
secondary bonding is apparent, and in each of 5 and 8 where O–H…O hydrogen bonding is 
present leading to a two-dimensional array and zig-zag chains, respectively.  The organotin 
compounds were evaluated for their anti-bacterial activity against 15 human bacterial 
pathogens.  Based on disc diffusion and minimum inhibitory concentration assays, the two 
triphenyltin species, 2 and 6, and di-n-butyl species, 7, are effective against both Gram-
positive and Gram-negative bacteria, including methicillin resistant Staphylococcus aureus 
(MTCC 381123) and Shigella flexneri (ATCC 12022), a causative agent for shigellosis.  
Time-kill assays showed that 2 and 6 had both time- and concentration-dependent anti-
bacterial effects against susceptible bacteria.  Cell viability assays showed that 2 and 6 were 
moderately toxic to a normal cell line, that is, human embryonic kidney 293T (HEK293T). 
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Adamantane (tricyclo-decane) is the smallest archetypal of diamondoid-hydrogen-terminated 
hydrocarbons with a diamond-like structure and its derivatives are compounds with high 
symmetry and striking impact [1-3]. The applications of adamantane derivatives in biology 
have grown at a rate comparable to the advancement of Amantadine (1-adamantylamine) 
chemistry. Amantadine became the forerunner of adamantane-based drug discovery due to its 
potent anti-Influenza A activity [4,5]. While Amantadine is no longer endorsed as an anti-
Influenza A agent because of the development of resistance to this drug, it has been 
superseded by second-generation derivatives, such as Memantine (3,5-dimethyl-1-
adamantanamine), with a total of seven adamantane-based drugs being approved for clinical 
use. However, these drugs were not discovered using modern high throughput screening 
strategies and their properties were typically determined on the basis of developing 
commercially available adamantane derivatives such as Amantadine or adamantane 
carboxylic acids. The adamantane moiety is widely incorporated in design and synthesis of 
new drugs in order to increase the stability and lipophilicity of molecules, thereby improving 
their pharmacokinetics [5-7]. The adamantyl moiety can be suitably tailored to fit the cavities 
of various host molecules such as cyclodextrins [8-10], can act as a blocking agent for 
cellular ion channels [11,12] and can also be integrated into the lipophilic part of the lipid 
bilayer so drug transfer can be made through cell membranes [13]. The value of the 
adamantyl group in drug design is multi-dimensional and its therapeutic aspects have been 
summarised [14]. 
While the adamantyl functionality has been widely utilised for anti-viral, anti-
microbial and anti-cancer drugs [5,14], with recent attention focused on adamantane-based 
compounds for various biological applications [15-20], they are rarely used as ligands. Metal 
complexes of Pd(II), Pt(II), Cu(II) [21,22] and Ag [23] with admantane derivatives have 
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demonstrated anti-cancer and strong anti-microbial actions. Adamantane-based compounds 
are a multifaceted building block due to its rigid and precisely defined geometrical shape, 
steric demand and physical properties [24]. It can function as an anchoring unit for self-
assembled monolayers, ensuring fixed angles of the adsorbed molecule relative to the metal 
surface [25]. Diamondoid-decorated Sn/S clusters were also accomplished by grafting 
adamantane units upon mono- and poly-functionalisation to bind Sn/S precursor clusters [26]. 
With the advent of a large variety of functionalisation on the adamantane core and the 
availability of even more lipophilic diamondoid building blocks discussed above, much is 
anticipated for the use of these unique hydrocarbons as modifiers or enhancers of active 
pharmacophores, an arena for future drug development. Complementing the above, research 
activities in the field of inorganic and organic chemistry of tin have advanced steadily due to 
their structural diversity and chemical applications, such as catalysis [27,28], antiproliferative 
activity [29], as well as biological applications [30-32]. A prominent element in anti-bacterial 
research is tin, usually present as an organometallic species, and a comprehensive review of 
the potential of these compounds as anti-bacterial agents has appeared [33]. In recent years, a 
broad range of synthetic organotin compounds have been investigated it his context including 
those of dithiocarbamates [34], hydroxamates [35], thiosemicarbazones [36] and, especially, 
carboxylates [37,38], sometimes derived from organic anti-bacterial agents, such as 
Ciprofloxacin [39]. The carboxylates chosen in the present study are derived from the 
symmetric cage compound adamantane, which is, as mentioned above, lipophilic in nature. 
While the anti-viral and anti-Parkinson effects of adamantane and derivatives are now well 
established [5] with a more recent development being the approval of an adamantane-1-
carboxamide derivative (ABC294640), a sphingosuine kinase inhibitor, which is an anti-
cancer drug used for the treatment of solid tumours [40]. 
With the above in mind, the current research deals with synthesis and characterisation 
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of organotin(IV) compounds with adamantane-1-carboxylate (L1) and 2-(adamantan-1-
yl)acetate (L2) ligands (Scheme 1), which led to the isolation of various compounds of 
compositions Me3Sn(L1) (1), Ph3Sn(L1) (2), {[Me2Sn(L1)]2O}2 (3), [BzSn(O)(L1)]6 (4), 
Me3Sn(L2)OH2 (5), [Ph3Sn(L2)]n (6), Bu2Sn(L2)2 (7), Bz2Sn(L2)2OH2 (8) and [BzSn(O)(L2)]6 
(9). Detailed structural information of compounds 1-9 in solution was obtained from 
multinuclear NMR spectroscopy, while single-crystal X-ray diffraction results provided 
information on the solid-state organisation of organotin(IV) compounds 2-8 in their crystals.  
In addition, the anti-bacterial activity of five of the new organotin compounds (1, 2, 5-7) was 
evaluated against 15 bacterial species using disc diffusion, MIC and MBC assays.  Time-kill 
assays were conducted to determine the preliminary pharmacokinetics of the most active 
compounds, namely, 2 and 6, were also conducted to assess the inhibition effects, i.e. 
bacteriostatic or bactericidal.  Finally, the preliminary cytotoxicity effects of the compounds 
2 and 6 were evaluated on a representative normal cell line, i.e. the human embryonic kidney 








Scheme 1. Synthetic methodologies used for obtaining organotin(IV) compounds 1-9. The 
numbers at the pro-ligands (HL1 and HL2) denote the atom-numbering protocol used for the 
NMR signal assignment. 
 
2. Experimental 
2.1. Materials and physical measurements  
Solvents and other general reagents used in this work were purified according to standard 
procedures [41]. Adamantane-1-carboxylic acid, 2-(adamantan-1-yl)acetic acid, Me2SnO, 
Me3SnCl (Aldrich), Ph3SnCl, Ph3SnOH (Alfa Aesar) and Bu2SnO (Merck) were used without 
further purification. Bz3SnOH and Bz2SnCl2 were prepared according to literature procedures 
[42,43]. Note: The reaction for obtaining compound 8 can be conducted in toluene; however, 
synthetic convenience, particularly in response to the high boiling point of toluene, led to the 
choice of benzene. Care in handling benzene should be exercised. The same comment is valid 
for the other compounds wherever applicable. 
Melting points were measured using a Büchi M-560 melting point apparatus and are 
uncorrected. Elemental analyses were performed using a Perkin Elmer 2400 series II 
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instrument. IR spectra in the range 4000-400 cm–1 were obtained either on a Perkin Elmer 
Spectrum BX series or Bruker alpha-II FT-IR spectrophotometer with samples investigated 
as KBr discs (ESI Figs. S1-S9). The 1H and 13C NMR spectra were recorded on a Bruker 
AMX 400 spectrometer and measured at 400.13 and 100.62 MHz, respectively (ESI Figs. 
S10-S27). 119Sn NMR spectra were measured on a JEOL Zeta ECZ 400R spectrometer at 
149.08 MHz (ESI Figs S28). The 1H, 13C and 119Sn chemical shifts were referenced to Me4Si 
(δ 0.00 ppm), CDCl3 (δ 77.00 ppm) and Me4Sn (δ 0.00 ppm), respectively. 
 
2.2. Synthesis of the sodium salts 
2.2.1. Sodium adamantane-1-carboxylate, Na(L1) 
A solution of sodium bicarbonate (0.46 g, 5.47 mmol) in hot water (5 mL) was added drop-
wise to a suspension of HL1 (0.50 g, 2.77 mmol) in hot water (10 mL) and digested for 1 h on 
a water bath. The resulting clear solution was filtered while hot. The filtrate was concentrated 
to dryness, treated with anhydrous methanol and finally dried in vacuo. The dried solid was 
extracted with anhydrous methanol with occasional warming on a water bath and filtered 
while hot. Evaporation of the filtrate afforded an amorphous, colourless powder, which was 
dried in vacuo. The solid was heated at reflux for 2 h in anhydrous toluene using a Dean-
Stark apparatus to remove traces of moisture. Then, the solvent was removed on a rotary 
evaporator and the product dried in vacuo. Yield (0.51 g, 90%), M.p.: >350 °C. IR 
absorptions (cm-1): 3630, 3397, 2908, 2848, 1655 ν(OCO)asym, 1623, 1527, 1452, 1410, 1343, 
1315, 1260, 1180, 1104, 906, 799, 766, 683, 608. 
 
2.2.2. Sodium 2-(adamantan-1-yl)acetate, Na(L2) 
An analogous method to that used for the preparation of Na(L1) was followed, using 2-
(adamantan-1-yl)acetic acid. The product was recrystallised from anhydrous methanol, giving 
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a colourless powder of Na(L2) in 50% yield. M.p.: >350 °C. IR absorption (cm-1): 3421, 
2094, 2847, 1631 ν(OCO)asym, 1575, 1556, 1440, 1408, 1344, 1313, 1146, 1101, 797, 663. 
 
2.3. Synthesis of organotin(IV) compounds 1-9 
2.3.1. Synthesis of Me3Sn(L1) (1) 
Me3SnCl (0.50 g, 2.50 mmol) in methanol (20 mL) was added to a clear solution of NaL1 
(0.51 g, 2.50 mmol) in methanol (30 mL) with continuous stirring. The reaction mixture was 
then refluxed for 5 h and filtered while hot to remove NaCl. The filtrate was evaporated using 
a rotary evaporator; the residue washed twice with hexane (2 × 0.5 mL) and dried in vacuo. 
The residue was extracted into toluene and filtered to remove any suspended particles. The 
slow evaporation of the filtrate at room temperature for several days afforded colourless 
crystals of 1. Yield 0.61 g (70%), M.p.: 190-192 °C. Anal. found. C, 48.88; H, 6.78. Calcd. 
for C14H24O2Sn: C, 49.02; H, 7.05%. IR absorptions (cm-1): 3433, 2904, 2851, 1591 
ν(OCO)asym, 1450, 1374, 1363, 1306, 1189, 1110, 1088, 779, 764, 679, 554, 546. 1H NMR 
(CDCl3) δH (ppm): 1.99 [s, 3H, H-4], 1.87 [s, 6H, H-3], 1.70 [s, 6H, H-5], 0.50 [s, 9H, H-1*] 
[2J(1H-119Sn) = 60 Hz]. 13C NMR (CDCl3) δC (ppm): 183.80 [C-1], 40.62 [C-2], 39.41 [C-3], 
36.60 [C-5], 28.14 [C-4], –2.48 [1J(13C-119Sn) = 399 Hz, C-1*]. 119Sn NMR (CDCl3): δSn 
(ppm): 125.0. 
 
2.3.2. Synthesis of Ph3Sn(L1) (2) 
Ph3SnOH (0.50 g, 1.38 mmol) in toluene (50 mL) was added to a clear solution of HL1 (0.25 
g, 1.38 mmol) in toluene (15 mL). The reaction mixture was heated at reflux for 5 h using a 
Dean-Stark apparatus and a water-cooled condenser, filtered while hot and the filtrate 
evaporated to dryness. The residue was washed with anhydrous hexane (2 × 0.5 mL) and 
dried in vacuo. The residue was extracted into toluene and filtered to remove any suspended 
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particles. Slow evaporation of the filtrate at room temperature yielded microcrystalline 
material. Several recrystallisation cycles from toluene afforded colourless crystals of 2. 
Yield: 0.50 g (68%). M.p.: 140-142 °C. Anal. found. C, 65.58; H, 5.48. Calcd. for 
C29H30O2Sn: C, 65.81; H, 5.71%. IR absorptions (cm-1): 3066, 2905, 2846, 1624 ν(OCO)asym, 
1480, 1451, 1430, 1342, 1297, 1255, 1180, 1105, 1079, 806, 728, 698, 684, 575. 1H NMR 
(CDCl3) δH (ppm): 7.78-7.63 [m, 6H, H-2*], 7.43 [m, 9H, H-3*/H-4*], 1.99 [s, 3H, H-4], 
1.94 [s, 6H, H-3], 1.70 [s, 6H, H-5]. 13C NMR (CDCl3) δC (ppm): 184.87 [C-1], 138.76 
[1J(13C-119Sn) = 645 Hz, C-1*], 136.78 [2J(13C-119Sn) = 48 Hz, C-2*], 129.90 [4J(13C-119Sn) = 
10 Hz, C-4*], 128.77 [3J(13C-119Sn) = 63 Hz, C-3*], 40.58 [C-2], 39.39 [C-3], 36.51 [C-5], 
28.07 [C-4]. 119Sn NMR (CDCl3) δSn (ppm): –118.7. 
 
2.3.3. Synthesis of {[Me2Sn(L1)]2O}2 (3) 
A suspension of Me2SnO (0.20 g, 1.21 mmol) and HL1 (0.21 g, 1.21 mmol) in anhydrous toluene 
(40 mL) was refluxed for 5 h in a flask equipped with a Dean-Stark water separator and a water-
cooled condenser. The clear reaction mixture was filtered while hot and the filtrate evaporated to 
dryness. The residue was washed with anhydrous hexane (3 × 1 mL) and dried in vacuo. The 
residue was extracted in boiling benzene and filtered while hot. The slow evaporation of the 
filtrate furnished colourless crystals of 3. Yield: 0.25 g (81%). M.p.: 277-279 °C. Anal. found. C, 
46.28; H, 6.66. Calcd. for C52H84O10Sn4: C, 46.47; H, 6.30%. IR absorptions (cm-1): 3450, 2905, 
2849, 1634 ν(OCO)asym, 1546, 1452, 1416, 1332, 1313, 1291, 1250, 791, 787, 654, 521, 504, 480. 
1H NMR (CDCl3) δH (ppm): 1.99 [s, 3H, H-4], 1.80 [s, 6H, H-3], 1.69 [m, 6H, H-5], 0.79 and 
0.70 [s, 6H H-1*]. 13C NMR (CDCl3) δC (ppm): 184.86 [C-1], 41.15 [C-2], 39.43 [C-3], 36.63 
[C-5], 28.16 [C-4], 9.66 and 6.85 [C-1*]. 119Sn NMR (CDCl3) δSn (ppm): –190.0 and –193.4. 
 
2.3.4. Synthesis of [BzSn(O)(L1)]6 (4) 
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An analogous method to that used for the preparation of 3 was followed using Bz3SnOH 
(0.20 g, 0.48 mmol) and HL1 (0.09 g, 0.48 mmol). The product was crystallised from a large 
volume of anhydrous toluene, giving colourless crystals of 4 upon slow evaporation. Yield: 
0.15 g (75%). M.p.: 340-342 °C. Anal. found. C, 53.28; H, 5.08. Calcd. for C108H132O18Sn6: 
C, 53.37; H, 5.47%. IR absorptions (cm-1): 2904, 2849, 1573 ν(OCO)asym, 1524, 1493, 1452, 
1427, 1312, 1113, 755, 693, 627, 592, 496. 1H NMR (CDCl3) δH (ppm): 7.27 [t, 2H, H-3*], 
7.17 [t, 2H, H-4*], 7.02 [t, 1H, H-5*], 2.70 [s, 2J(1H-119Sn) = 148 Hz, 2H, H-1*], 1.90 [s, 3H, 
H-4], 1.67-1.53 [m, 12H, H-3/H-5]. 13C NMR (CDCl3) δC (ppm): 185.04 [C-1], 139.33 [C-
2*], 129.23 [C-4*], 127.81 [C-3*], 124.05 [C-5*], 42.43 [C-2], 38.60 [C-3], 36.61 [C-5], 34.34 
[C-1*], 28.12 [C-4]. 119Sn NMR (CDCl3) δSn (ppm): –520.6. 
 
2.3.5. Synthesis of Me3Sn(L2)OH2 (5) 
An analogous method to that used for the preparation of 1 was followed using Me3SnCl (0.50 
g, 2.50 mmol) and NaL2 (0.55 g, 2.57 mmol). The product was crystallised from ethanol, 
giving colourless crystals of 5 upon slow evaporation. Yield: 0.75 g (81%). M.p.: 180-182 
°C. Anal. found. C, 48.08; H, 7.48. Calcd. for C15H28O3Sn: C, 48.03; H, 7.52%. IR 
absorptions (cm-1): 2925, 2900, 1605 ν(OCO)asym, 1442, 1377, 1358, 1344, 1297, 1192, 1148, 
1100, 783, 720, 677, 558, 549. 1H NMR (CDCl3) δH (ppm): 4.71 [s, 2H, H2O], 2.01 [s, 2H, 
H-2], 1.89 [s, 3H, H-5], 1.64-1.55 [m, 12H, H-4/H-6], 0.47 [s, 2J(1H-119Sn) = 56 Hz, 9H, H-
1*]. 13C NMR (CDCl3) δC (ppm): 177.66 [C-1], 49.52 [C-2], 42.43 [C-4], 36.82 [C-6], 32.41 
[C-3], 28.64 [C-5], –2.41 [1J(13C-119Sn) = 399 Hz, C-1*]. 119Sn NMR (CDCl3) δSn (ppm): 
125.6. 
 
2.3.6. Synthesis of [Ph3Sn(L2)]n (6) 
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An analogous method to that used for the preparation of 1 was followed using Ph3SnCl (0.50 
g, 1.29 mmol) and NaL2 (0.30 g, 1.38 mmol). The product was crystallised from ethanol, 
giving colourless crystals of 6 upon slow evaporation. Yield: 0.55 g (78%). M.p.: 138-140 
°C. Anal. found. C, 66.78; H, 6.08. Calcd. for C30H32O2Sn: C, 66.32; H, 5.94%. IR 
absorptions (cm-1): 3063, 3048, 2905, 2848, 1574 ν(OCO)asym, 1543, 1519, 1482, 1429, 1418, 
1403,1311, 1080, 728, 698. 1H NMR (CDCl3) δH (ppm): 7.82 [m, 6H, H-2*], 7.51 [m, 9H, H-
3*/H4*], 2.25 [s, 2H, H-2], 1.95 [s, 3H, H-5], 1.72-1.57 [m, 12H, H-4/H-6]. 13C NMR 
(CDCl3) δC (ppm): 179.29 [C1], 138.65 [1J(13C-119Sn) = 649 Hz, C-1*], 136.90 [2J(13C-119Sn) 
= 48 Hz, C-2*], 129.96 [4J(13C-119Sn) = 13 Hz, C-4*], 128.76 [3J(13C-119Sn) = 62 Hz, C-3*], 
48.72 [C-2], 42.37 [C-4], 36.67 [C-6], 32.81 [C-3], 28.58 [C-5]. 119Sn NMR (CDCl3) δSn 
(ppm): –117.7. 
 
2.3.7. Synthesis of Bu2Sn(L2)2 (7) 
An analogous method to that used for the preparation of 2 was followed using Bu2SnO (0.25 
g, 1.00 mmol) and HL2 (0.39 g, 2.00 mmol). The product was crystallised from ethanol, 
giving colourless crystals of 7 upon slow evaporation. Yield: 0.45 g (72%). M.p.: 72-74 °C. 
Anal. found. C, 62.28; H, 7.98. Calcd. for C32H52O4Sn: C, 62.04; H, 8.46%. IR absorptions 
(cm-1): IR absorptions (cm-1): 2952, 2905, 2847, 1589 ν(OCO)asym, 1451, 1378, 1147, 1125, 
727, 674. 1H NMR (CDCl3) δH (ppm): 2.07 [s, 2H, H-2], 1.91 [s, 3H, H-5], 1.65-1.29 [m, 
16H, H-4/H-6/H-1*/H-2*], 1.34-1.29 [m, 2H, H-3*], 0.84 [t, 3H, H-4*]. 13C NMR (CDCl3) 
δC (ppm): 182.45 [C-1], 48.69 [C-2], 42.44 [C-4], 36.71 [C-6], 32.58 [C-3], 28.57 [C-5], 
26.79 [C-2*], 26.41 [C-3*], 25.16 [1J(13C-119Sn) = 591 Hz, C-1*], 13.52 [C-4*]. 119Sn NMR 
(CDCl3) δSn (ppm): –150.0. 
 
2.3.8. Synthesis of Bz2Sn(L2)2OH2 (8) 
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An analogous method to that used for the preparation of 1 was followed using Bz2SnCl2 (0.25 
g, 0.67 mmol) and NaL2 (0.29 g, 1.34 mmol). The product was crystallised from ethanol, 
giving colourless crystals of 8 upon slow evaporation. Yield: 0.35 g (73%). M.p.: 110-112 
°C. Anal. found. C, 64.98; H, 7.40. Calcd. for C38H50O5Sn: C, 64.69; H, 7.14%. IR 
absorptions (cm-1): 2908, 2847, 1653, 1585 ν(OCO)asym, 1543, 1492, 1452, 1432, 1409, 1147, 
1104, 1050, 766, 754, 696, 671, 620. 1H NMR (CDCl3) δH (ppm): 7.11-7.00 [m, 10H, H-
3*/H-4*/H-5*], 4.53 [s, 2H, H2O], 2.88 [s, 2J(1H-119Sn) = 100 Hz, 2H, H-1*], 1.87-1.85 [m, 
10H, H-2/H-5], 1.63-1.52 [m, 12H, H-4], 1.50 [s, 12H, H-6]. 13C NMR (CDCl3) δC (ppm): 
181.48 [C-1], 136.50 [C-2*], 128.31 [C-4*], 127.94 [C-3*], 124.80 [C-5*], 47.86 [C-2], 41.98 
[C-4], 36.36 [C-6], 33.57 [C-3], 32.06 [C-1*], 28.18 [C-5]. 119Sn NMR (CDCl3) δSn (ppm): –
244.8. 
 
2.3.9. Synthesis of [BzSn(O)(L2)]6 (9) 
An analogous method to that used for the preparation of 3 was followed using Bz3SnOH 
(0.30 g, 0.73 mmol) and HL2 (0.14 g, 0.73 mmol). The product crystallised as a fine, 
colourless microcrystalline material from a large volume of hot anhydrous toluene when 
heated at water-bath temperature. Yield: 0.25 g (81%). M.p.: 278-279 °C. Anal. found. C, 
54.28; H, 6.18. Calcd. for C114H144O18Sn6: C, 54.45; H, 5.77%. IR absorptions (cm-1): 2900, 
2847, 1586 ν(OCO)asym, 1536, 1449, 1413, 1362, 1346, 1308, 1151, 1097, 1077, 991, 728, 
696, 621, 553, 524. 1H NMR (CDCl3) δH (ppm): 7.11-7.00 [m, 5H, H-3*/H-4*/H-5*], 2.88 [s, 
2J(1H-119Sn) = 100 Hz, 2H, H-1*], 1.85 [m, 5H, H-2/H-5], 1.60-1.50 [m, 12H, H-4/H-6]. 13C 
NMR (CDCl3) δC (ppm): 181.48 [C-1], 136.52 [C-2*], 128.31 [C-4*], 127.92 [C-3*], 124.78 
[C-5*], 47.91 [C-2], 41.97 [C-4], 36.35 [C-6], 33.62 [C-3], 32.05 [C-1*], 28.17 [C-5]. 119Sn 
NMR (CDCl3) δSn (ppm): –520.7. 
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(Note: Numbers 1*, 2*, 3*, 4* and 5* refer to the proton and carbon atoms of the Sn-R 
moiety). 
 
2.4. Single crystal X-ray structure determination 
Crystal data and refinement details for 2-8 are included in Table 1. Intensity data for the 
colourless crystals were measured at room temperature on an Agilent Xcalibur Eos Gemini 
diffractometer equipped with a CCD area detector and graphite-monochromated Mo Kα 
radiation (λ = 0.71073 Å). Data reduction and empirical absorption corrections, based on a 
multi-scan technique, were applied  [44]. The structures were solved by direct methods [45] 
and refined on F2 with anisotropic displacement parameters and C-bound H atoms in the 
riding model approximation [46]. For 5 and 8, the oxygen-bound H atoms were refined with a 
distance restraint O‒H = 0.82±0.01 Å. A weighting scheme of the form w = 1/[σ2(Fo2) + 
(aP)2 + bP] where P = (Fo2 + 2Fc2)/3) was introduced for each refinement. For 5, the 
maximum and minimum residual electron density peaks of 1.05 and 1.70 eÅ-3, respectively, 
were located 1.83 and 1.39 Å from the H2o and H15a atoms, respectively, i.e. in chemically 
non-relevant positions. The molecular structure diagrams were generated by ORTEP for 
Windows [47] and the packing diagrams with DIAMOND [48]. Additional data analysis was 
made with PLATON [49]. 
Insert Table 1 
 
2.5.  Screening for anti-bacterial activity 
2.5.1.  Bacterial species 
Fifteen clinically relevant bacterial species were used in this study, purchased from either the 
American Type Culture Collection (ATCC) or the Malaysian Type Culture Collection 
(MTCC).  Six of these pathogens were Gram-positive bacteria: Enterococcus faecalis (ATCC 
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33186), Enterococcus faecium (ATCC 19434), Methicillin Resistant Staphylococcus aureus 
(MRSA; MTCC 381123), Staphylococcus epidermidis (ATCC 700576), Streptococcus 
pneumoniae (ATCC 49619) and Streptococcus pyogenes (ATCC 49399).  The nine Gram-
negative bacteria were Escherichia coli (ATCC 11775), Escherichia coli clinical isolate K1 
(MTCC 710859), Klebsiella pneumoniae (ATCC 13883), Klebsiella quasipneumoniae 
(ATCC 700603), Pseudomonas aeruginosa (ATCC 10145), Proteus vulgaris (ATCC 49990), 
Salmonella enterica (ATCC 14028), Shigella flexneri (ATCC 12022) and Vibrio 
parahaemolyticus (ATCC 17802).  The bacterial cultures were maintained on nutrient agar 
(Oxoid) and sub-cultured on a weekly basis. Prior to all experiments, the bacteria were 
cultured in Mueller-Hinton Broth (MHB; Oxoid) and incubated overnight at 37 °C. 
 
2.5.2. Disc diffusion assay 
The anti-bacterial activities of the trial compounds were screened using a conventional disc 
diffusion method in accordance with the Clinical and Laboratory Standards Institute (CLSI) 
guidelines. An inoculum suspension of each bacterial species was prepared by diluting the 
turbidity of overnight-grown cultures to OD625 nm = 0.09-0.13, equivalent to 1-2 x 108 
colony forming units (CFU)/mL, using phosphate buffer saline (PBS; Sigma-Aldrich).  The 
adjusted inoculum suspension was then spread on Mueller-Hinton agar (MHA; Oxoid) using 
a sterile cotton swab.  Sterile filter paper discs (6 mm in diameter) were aseptically placed on 
the agar followed by the addition of 5 µL of each trial compound with a stock concentration 
of 6 mg/mL, resulting in discs containing 30 µg of compound.  Two anti-biotics, tetracycline 
(30 µg/disc) and chloramphenicol (30 µg/disc), were included in the experiments as positive 
controls while discs containing 5 µL of each DMSO and broth medium were included as 
solvent and negative controls, respectively.  The plates containing the discs were incubated at 
37 °C for 24 h.  The anti-bacterial activities of the trial compounds were determined by 
16 
 
measuring the diameter of inhibition zones formed around the discs.  Three independent 
experiments were conducted for each compound. 
 
2.5.3. Minimum inhibitory concentration (MIC) and Minimum bactericidal 
concentration (MBC) assays 
Following disc diffusion screening, the determination of the anti-bacterial activity of selected 
active compounds was tested using the broth dilution method to determine MIC and MBC 
values.  The broth-dilution method was conducted according to CLSI protocols.  Each test 
compound was taken up in DMSO to a concentration of 2 mg/mL, followed by a 2-fold 
dilution with DMSO.  Graded concentrations of the trial compounds (5 µl) were added into 
each well of 96-well microplates, achieving final concentrations ranging from 0.78 to 100 
µg/mL.  The controls included in the assay were anti-biotics (Tetracycline and 
Chloramphenicol), DMSO (solvent) and broth medium (negative).  After the addition of 
compounds and controls, inoculum suspension was added to wells, achieving 105 CFU/mL of 
cells in each well.  Media with no bacterial suspension were also included as an additional 
negative control in the assay.  The microplates were incubated for 24 h at 37 °C.  The 
presence of turbidity observed in each well indicated bacterial growth.  The MIC was 
determined as the lowest concentration at which no turbidity was seen.  The suspension in 
each well was separately aliquoted and transferred onto MHA.  After a 24 h incubation at 37 
°C, the MBC was determined as the minimum concentration of a compound where no viable 
colony count was observed. 
 
2.5.4. Time-kill assay 
The anti-bacterial activities of two selected compounds, i.e. 2 and 6, over time were 
evaluated using a time-kill assay.  The inoculum suspension with a bacterial density of 105 
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CFU/mL was used in this assay.  Each test compound (100 µL) was added to the inoculum 
suspension, giving a final volume of 10 mL and achieving final concentrations of ½ × MIC, 1 
× MIC and 2 × MIC (MIC values were as determined in section 2.5.3).  A growth control 
comprising only bacterial species was included in each replicate.  All treated and untreated 
cultures were incubated at 37 °C on an orbital shaker operating at 200 r.p.m.  The cultures 
were removed from shaker at each time interval of incubation (0, 1, 2, 4, 8 and 24 h).  A total 
of 300 µL of suspension, each aliquot being100 µL, was removed from the cultures and each 
10-fold titrated in 0.9% normal saline.  Next, 10 µL of each dilution was then plated on 
MHA.  All plates were incubated at 37 °C overnight.  The experiments were performed in 
triplicate.  The data were analysed as killing curves by plotting the log10[colony forming unit 
per millilitre (CFU/mL)] versus time (h).  The viable bacterial cell counts for the time-kill 
end point determination, i.e. bactericidal activity, was defined as a reduction of ≥ 3log10 
(CFU/mL) relative to the initial inoculum, whereas the bacteriostatic activity corresponds to 
< 3log10 (CFU/mL) reduction relative to the initial inoculum. 
 
2.5.5. Cell viability assay 
The cytotoxicity of the trial compounds against human embryonic kidney cell line, HEK293T 
(ATCC CRL-3216) was studied using an MTT proliferation assay.  The HEK293T cells were 
seeded in each well of a 96-well micro plate at a cell density of 2 × 104 cells/mL.  Each test 
compound was dissolved and further 2-fold serial-diluted in DMSO.  The pre-seeded 
HEK293T cells were treated with the compounds (pro-ligands: HL1, HL2, organotin 
compounds: 1, 2, 5-7, organotin precursors: Me3SnCl, Ph3SnOH, Bu2SnCl2) at final 
concentrations ranging from 0.78 to 100 µg/mL with 1% (v/v) DMSO.  Treatment lasted for 
24 h at 37 °C.  10 µL of MTT (Goldbio) solution was added to each well.  The plate was 
incubated for a further 4 h.  The medium was removed from each well and replaced with 
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DMSO to dissolve insoluble formazan formed in the wells.  The absorbance was measured at 
540 nm through microplate reader (Tecan Infinite-M200).  The 50% cytotoxic concentration 
(CC50) of each trial compound was determined by plotting cell viability in the presence of 
different concentrations of the trial compounds.  The results are the average of three 
independent experiments. 
 
3. Results and discussion  
3.1. Synthesis and characterisation of 1-9 
The reactions of R3SnCl (R = methyl or phenyl) with sodium adamantane-1-carboxylate, 
Na(L1) and sodium 2-(adamantan-1-yl)acetate, Na(L2) in methanol affords Me3Sn(L1) (1), 
Me3Sn(L2)OH2 (5) and [Ph3Sn(L2)]n (6). On the other hand, the reactions of Bz3SnOH with 
adamantane-1-carboxylic acid (HL1) and 2-(adamantan-1-yl)acetic acid (HL2) in toluene at reflux 
temperature undergoes a facile double Sn-C bond cleavage to give the monoorganostannoxanes 
[BzSn(O)(L1)]6 (4) and [BzSn(O)(L2)]6 (9), respectively. In contrast, the reaction of Ph3SnOH 
with HL1 affords Ph3Sn(L1) (2), where the Sn-C bonds are found to be robust. Diorganotin(IV) 
compounds of compositions {[Me2Sn(L1)]2O}2 (3) and Bu2Sn(L2)2 (7) were obtained from 
reactions of the corresponding R2SnO (R = methyl or butyl) with the appropriate HL1/HL2, while 
Bz2Sn(L2)2OH2 (8) was obtained by metathesis reaction of Bz2SnCl2 with Na(L2). The synthetic 
details are given in the Experimental Section (see also Scheme 1).  The organotin(IV) 
compounds have been characterised by IR, 1H, 13C and 119Sn NMR spectroscopic techniques. The 
FT-IR spectra of compounds 1-9 show a characteristic band for the νasym(OCO) vibration, which 
is significantly shifted (refer to the IR data for specific shift assignments and ESI Figs 1-9 for 
complete spectra of compounds) from their relative positions in pro-ligands HL1 (νasym(OCO) = 
1693 cm-1) and HL2 (νasym(OCO) = 1710 cm-1), indicating coordination of the carboxylate group 
to the organotin fragments [50]. In addition, a characteristic medium to strong intensity band was 
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detected for compound 3 at ~ 655 cm-1 and for 4 and 9 at ~ 625 cm-1 that is assigned to the ν(Sn-
O-Sn) vibration [51,52]. Compounds 1-9 display the anticipated 1H and 13C NMR signals in 
solution, revealing the general spectral patterns (ESI Figs S10-S27). The absence of the 
carboxylic/acetic acid OH proton signals of HL1 and HL2 in the compounds 1-9 supports the 
binding to the tin centre. For the ligand and Sn-R moieties, the number of protons calculated 
from the integration values in the 1H NMR spectra agree with the proposed molecular structures 
of 1-9 (see Experimental Section). Compound 3 displayed two sets of 1H and 13C signals for the 
methyl groups, which is in accord with the pairwise heterotopic non-equivalence of the exocyclic 
and endocyclic Me2Sn moieties. The solution structures of compounds 1-9 were determined by 
119Sn NMR chemical shifts in CDCl3 and are collated in ESI Figs S28. Trimethyltin(IV) 
compounds 1 and 5 exhibit 119Sn NMR chemical shifts at around +125 ppm, which is indicative 
of four-coordinated tin atoms [53]. The triphenyltin(IV) compounds 2 and 6 exhibited a single 
sharp resonance at higher fields at around −118 ppm, similar to other four-coordinated 
triphenyltin carboxylates [54]. Thus, from the δ (119Sn) NMR values it may be inferred that the 
five-coordinate geometries of the tin atoms in the solid-state structures of 1, 5 and 6 (either due to 
coordination of a water molecule or bidentate bridging) are not retained in solution (see 
Experimental Section). The 119Sn NMR spectrum of the tetranuclear dimethyltin(IV) compound 
{[Me2Sn(L1)]2O}2 (3) with a bis(dicarboxylatotetraorganodistannoxane) framework displays a 
pair of resonances at around –190 and –193 ppm, confirming the presence of endo- and exo- 
cyclic tin atoms [51,52]. The δ (119Sn) chemical shifts in the ranges –200 to –400, –90 to –190 
and +200 to –60 ppm, respectively, have been associated with six-, five- and four-coordinate tin 
centres bearing alkyl groups [55]. On this basis, the two chemically different tin atom centres, i.e. 
endo-Sn and exo-Sn, are assigned to be five-coordinate and the results are consistent with those 
revealed by X-ray crystallography (vide infra). This signifies that the coordination environments 
of the tin atoms are robust and retained in non-coordinating CDCl3 solution. The diorganotin(IV) 
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compounds of composition Bu2Sn(L2)2 (7) and Bz2Sn(L2)2OH2 (8) necessitate specific mention. 
The 119Sn NMR spectrum of 7 reveals a sharp signal at –150 ppm, consistent with those reported 
for other Bu2Sn(O2CR′)2 systems [56], implying that the same coordination pattern i.e. a 
trapezoidal-bipyramid as observed in the solid-state is preserved in solution. Compound 8 adopts 
a pentagonal-bipyramidal geometry in the solid-state (vide infra) and has a 119Sn NMR signal at 
around –245 ppm in CDCl3 solution. The observed chemical shift matches closely with five-
coordinated dibenzyltin(IV) Schiff base aminoacetate [57], but the observed chemical shift value 
is much lower than the value observed for structurally characterised six-coordinate 
dibenzyltin(IV) oxinates [58], and hence a conclusion about the coordination in solution could 
not be derived unambiguously. Lastly, the 119Sn NMR spectra of the monoorganostannoxanes 4 
and 9 each exhibited single sharp resonance at ca – 520 ppm, indicative of the equivalence of the 
six tin atoms in the molecules of [BzSn(O)(L1/2)]6, and this is corroborated by the observed drum 
structural motif [59,60]. 
 
3.2. Molecular structures of 2-8 
The crystal and molecular structures of three organotin(IV) derivatives of HL1, 2-4 
(Fig. 1), and four organotin(IV) derivatives of HL2, 5-8 (Fig. 2), have been established by X-
ray crystallography. The molecule in Ph3Sn(L1), 2, is illustrated in Fig. 1a and features an 
asymmetrically chelating carboxylate ligand with the Sn–O1 and Sn–O2 bond lengths being 
2.046(2) and 2.720(3) Å, respectively. The difference in the long and short Sn–O bond 
lengths amounts to approximately 0.67 Å and this is clearly reflected in the significant 
disparity in the associated C1–O1 and C1–O2 bond lengths of 1.295(4) and 1.220(4) Å, 
respectively. If the carboxylate ligand was considered monodentate, the C3O donor set would 
define a tetrahedral geometry with the range of tetrahedral angles being a narrow at 
94.89(9)°, for O1–Sn–C18, to a wide 118.43(9)°, for O1–Sn–C12, with the widest angle 
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clearly correlated with the close approach of the O2 atom to tin. If the Sn...O2 interaction was 
considered binding, the C3O2 donor set exhibits a far greater range of angles, being an acute 
52.31(9)°, for the O1–Sn–O2 chelate angle, to 146.14(8)°, for O2–Sn–C18. The parameter, τ, 
can be employed to measure the deviation of a five-coordinate geometry from the ideal 
square pyramidal, for which τ = 0.00, and trigonal bipyramidal (τ = 1.00) geometries [61]. 





Fig. 1. The molecular structures of (a) Ph3Sn(L1) (2; 25% probability level), (b) 
{[Me2Sn(L1)]2O}2 (3; 50% probability level) and (c) [BzSn(O)(L1)]6 (4; 25% probability 
level), showing the atom labelling schemes and anisotropic displacement parameters. The 
unlabelled atoms are related by the symmetry operation 2-x, 2-y, 2-z (3) and 2-x, 1-y, -z (4). 
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In 3, the carbon atoms are indicated by numbers only to reduce cluttering. Selected geometric 
parameters for the bridging carboxylate ligands in 3: Sn1–O4 = 2.141(3), Sn2–O5 = 2.140(3), 
C1–O4 = 1.260(5), C1–O5 = 1.252(5), Sn1–O6 = 2.167(3), Sn3–O7 = 2.139(3), C12–O6 = 
1.257(5), C12–O7 = 1.266(5), Sn3–O8 = 2.140(3), Sn2–O9i = 2.138(3), C23–O8 = 1.264(5), 
C23–O9 = 1.259(4) Å. 
 
The molecular structure of tetra-nuclear {[Me2Sn(L1)]2O}2, 3, is shown in Fig. 1b and 
is disposed about a crystallographic centre of inversion. The structure is constructed about a 
central Sn2O2 core, incorporating endocyclic Sn2 atoms, to which are linked two exocyclic 
Sn1 atoms; the O1 atom therefore, functions as a μ3-oxo ligand. The Sn2–O1 and Sn2–O1i 
bond lengths within the core are 2.1401(17) and 2.0427(16) Å, respectively, and are not 
equivalent indicating the core has the shape of a distorted diamond; symmetry operation (i): 
2-x, 2-y, 2-z. The Sn1–O1 bond length of 2.0171(16) is shorter than the Sn2–O1, O1i bond 
lengths. A further link between the exo- and endo-cyclic tin atoms is provided by a bidentate 
bridging carboxylate ligand with Sn1–O4 = 2.2843(18) Å and O5–Sn2i = 2.2251(19) Å bond 
lengths indicating a close to symmetric bridge; this is verified by the experimental 
equivalence of the C12–O4 and C12–O5 bond lengths of 2 × 1.256(3) Å. The remaining 
carboxylate ligand coordinates the exocyclic Sn1 atom in the monodentate mode with the 
Sn1–O2 bond length being 2.1697(16) Å. Consistent with this is the Sn1…O3 separation of 
2.987(3) Å and the disparity in the C1–O2 and C1–O3 bond lengths of 1.308(3) and 1.220(3) 
Å, respectively. The five-coordinate geometry about the Sn1 atom is based on a C2O3 donor 
set. The value of τ [61] is 0.55 indicating a significant distortion from the ideal trigonal-
bipyramidal geometry, presumably owing to the close approach of the O3 atom. More 
striking is the coordination geometry about the Sn2 atom, ostensibly also based on a C2O3 
donor set. However, the close approach of the O2 atom, derived from the monodentate 
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carboxylate ligand, at 2.7461(18) Å, clearly distorts the geometry. This is especially 
manifested in the wide C25–Sn2–C26 angle of 149.58(13)° which is approximately 17° 
wider than the C23–Sn1–C24 angle of 132.39(14)° and nearly 30° wider than the ideal angle 
of 120° for a trigonal-bipyramidal geometry. As a consequence, based on a C2O3 donor set, 
the value of τ = 0.24 [61], indicating a considerable distortion towards a square-pyramidal 
geometry with the O1 atom in the apical position. 
The molecular structure of hexa-nuclear [BzSn(O)(L1)]6, 4, is shown in Fig. 1c; the 
molecule is disposed about an inversion centre. This “drum” molecule features two stacked 
six-membered Sn3O3 rings rotated approximately 60° relative to each other and connected by 
a sequence of alternating Sn–O and O–Sn bonds; the structure, therefore, features μ3-oxo 
groups as for 3. The Sn–O(oxo) bond lengths lie in the experimentally equivalent range of 
2.083(2) Å, for Sn1–O2, to 2.098(3) Å, for Sn2–O1. Within the {Sn3O3}2 drum, diagonally 
opposite tin atoms are bridged by carboxylate ligands. The carboxylate ligands are 
symmetrically bridging and seen in the close equivalence in the pairs of Sn–O bond lengths 
and associated C–O bond length collated in the caption to Fig. 1. The final position in each of 
the hexa-coordinate geometries is occupied by the methylene-carbon atoms derived from the 
tin-bound benzyl substituents. The methylene-carbon atoms are trans to an oxo-oxygen atom 
as are each of the carboxylate-oxygen atoms. Each of the resultant CO5 coordination 
geometries is based on an octahedron. 
The molecular structure of Me3Sn(L2)OH2, 5, shown in Fig. 2a. The five-coordinate 
geometry about the tin atom is defined by the O1 atom derived from a monodentate 
carboxylate ligand, the O3 atom of the water molecule and three tin-bound methyl 
substituents. Evidence that the carboxylate ligand is coordinating in a monodentate mode is 
readily seen in the disparity of the Sn–O1 and Sn–O2 separations of 2.183(2) and 3.058(3) Å, 
respectively, and in the difference in associated C1–O1 and C1–O2 bonds, i.e. 1.288(4) and 
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1.235(5) Å, respectively. The Sn–O3(water) bond length of 2.447(4) Å is intermediate 
between these extremes. The value of τ [61] computes to 0.83, indicating a close to trans-
C3O2 trigonal-bipyramidal geometry. The minimal distortion of the trans O1–Sn–O3 angle, 
i.e. 176.12(11)°, from the ideal angle vindicates the negligible influence of the proximate O2 
atom. 
A one-dimensional coordination polymer is found in the structure of [Ph3Sn(L2)]n, 6. 
The asymmetric unit of 6 is represented in Fig. 2b. The carboxylate ligand is bidentate, 
bridging in an asymmetric mode with the Sn–O1 bond length of 2.190(2) Å being shorter 
than the Sn–O2i bond of 2.322(2) Å; symmetry operation (i): x, ½-y, -½+z. The closeness of 
the Sn–O bonds is reflected in the similarity of the C1–O1 and C1–O2 bonds of 1.274(3) and 
1.251(4) Å, respectively. The trans-C3O2 coordination geometry is based on a trigonal-
bipyramidal geometry with a value of τ = 0.75 [61]. The result of the bridging mode of 
coordination is a supramolecular coordination polymer, shown in Fig. 2c. The coordination 
polymer is propagated by glide-symmetry along the c-axis and has a zig-zag topology. 
The molecular structure of Bu2Sn(L2)2, 7, is shown in Fig. 2d. The molecule is 
disposed about a two-fold axis of symmetry with the tin atom lying on the axis, relating the 
carboxylate ligands and n-butyl groups about the axis. The tin atom is coordinated by an 
asymmetrically chelating carboxylate ligand with the Sn–O1 bond length of 2.102(2) Å being 
shorter than Sn–O2 of 2.535(3) Å; the difference in Sn–O bond lengths is reflected in the 
associated C1–O1 and C1–O2 bonds of 1.306(4) and 1.221(4) Å which differ by more than 
0.08 Å. The best description of the coordination geometry is one based on a skew-trapezoidal 
bipyramid, with the n-butyl groups orientated to lie over the weaker Sn–O2 bonds; the C13–
Sn–C13i bond angle is 132.4(2)° for symmetry operation (i): 1-x, y, 1½-z. Reflecting the 
trapezoidal nature of the O4 plane, the O1– Sn–O1 angle of 84.30(14)°, i.e. subtended by the 





Fig. 2. The molecular structures of (a) Me3Sn(L2)OH2 (5; 25% probability level), (b) 
[Ph3Sn(L2)]n (6; 25% probability level; the arrows indicate the links to generate the 
supramolecular, one-dimensional coordination polymer shown in (c)), (d) Bu2Sn(L2)2 7 (25% 
probability level) and (e) Bz2Sn(L2)2OH2 (8; 35% probability level), showing the atom 
labelling schemes and anisotropic displacement parameters. The unlabelled atoms are related 
by the symmetry operations 1-x, y, 1½-z (7) and 1½-x, ½-y, z (8). 
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As for 7, the molecular structure of Bz2Sn(L2)2OH2, 8, Fig. 2e, is also disposed about 
a two-fold axis of symmetry upon which lies the Sn and water-O3 atoms. An asymmetric 
mode of coordination is also noted for the independent carboxylate ligand with the Sn–O1 
bond length of 2.2255(18) Å being shorter than the Sn–O2 bond of 2.387(2) Å. This disparity 
is significantly less than in 7 and is reflected in the near equivalence of the C1–O1 and C1–
O2 bond lengths of 1.281(3) and 1.254(3) Å, respectively. The Sn-O3 bond length is 
2.429(3), i.e. longer than the other Sn–O bond lengths in the molecule. The five oxygen 
atoms define a pentagonal plane with the methylene-carbon atoms occupying positions above 
and below the plane, C13–Sn–C13i is 166.60(14)°, so the coordination geometry is best 
described as being trans-C2O5 pentagonal-bipyramidal; symmetry operation (i): 1½-x, ½-y, z. 
There are four basic structural motifs for molecules conforming to the general formula 
R3Sn(O2CR') [62]. With relatively few examples of oligomeric {R3Sn(O2CR')}4, exemplified 
by {(nBu)3Sn[O2C(2,6-C6H3F2]}4 [63], and {R3Sn(O2CR')}6, exemplified by 
{Ph2(Et)Sn(O2CMe)}6 [64], the predominate motifs are monomeric, as in 2, and polymeric, 
as in 6. Assuming significant bonding interactions for the second Sn–O connection in 2 (see 
above), the coordination geometries could be considered cis-C3O2 and trans-C3O2, 
respectively, for the monomeric and polymeric forms. The adoption of one form over the 
other can often be ascribed to steric effects in that bulky tin-bound substituents and/or 
carboxylate groups can mediate the formation of the Sn…O secondary bonding interaction 
[65,66]. The steric control over Sn…O secondary bonding interactions between tin and 
oxygen atoms in organotin carboxylates is well documented [67,68]. The difference between 
2 and 6 in the present study is a methylene substituent in the carboxylate ligand, which is 
sufficient to relieve steric strain in 6, allowing for the adoption of the observed coordination 
polymer. The structure of 3 conforms to the predominate structural motif for molecules of the 
general formula {[R2Sn(O2CR')]2O}2 [62], a commonly observed oxidation product in 
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organotin carboxylates, with variations to this motif found in the number of bridging 
carboxylate ligands [69]. Similarly, 4 conforms to the standard structural motif for molecules 
of the general formula [RSn(O2CR')O]6 [62]. The only literature precedent for a tin 
compound containing carboxylate ligands included in this study is found in the related drum 
structure [nBuSn(O)(L1)]6 [70]. A search of the Cambridge Structural Database [71] reveals 
over 80 structures related to 5, with the first of these, i.e. Me3Sn(O2CC5H4N-2), reported in 
1979 [72]. There are also many literature precedents for skew-trapezoidal bipyramidal 7, with 
variations relating to the asymmetry in the mode of coordination of the carboxylate ligands 
[73]. By contrast, there are less than 10 examples of structures conforming to pentagonal-
bipyramidal 8, with the prototype structure found in Cy2Sn(O2CMe)2(OH2) [74]. 
 
3.3. Molecular packing 
Based on the distance criteria assumed in PLATON [49], there are no directional interactions 
operating in the crystal of 2; a view of the unit cell contents is shown in ESI Fig. S29.  As for 2, 
no structure-directing interactions are apparent in the crystal of 3; a view of the unit cell 
contents is shown in ESI Fig. S30.  The presence of the bulky adamantyl groups in 4 again 
precludes the formation of directional interactions in the molecular packing of 4; a view of the 
unit cell contents is shown in ESI Fig. S31.  The possibility of hydrogen bonding occurs in the 
crystal of 5 and indeed, each of the water-bound hydrogen atoms forms a hydrogen bond with 
symmetry-related atoms of each carboxylate-O atom; geometric parameters characterising 
these are given in the caption to Fig. 3. As shown in Fig. 3a, the hydrogen bonds extend 
laterally to form a supramolecular layer with a zig-zag topology in the ab-plane featuring 16-
membered {…H…OCO…HOSnO}2 synthons. The layers stack along the c-axis without 





Fig. 3. Molecular packing sustained by hydrogen bonding in the crystals of 5 and 8: (a) 5, a 
view of the supramolecular layer in the ab-plane sustained by water-O–H…O(carboxylate) 
hydrogen bonding and (b) a view of the zig-zag supramolecular chain along the c-axis 
sustained water-O–H…O(carboxylate) hydrogen bonding.  Non-participating hydrogen atoms 
have been omitted for reasons of clarity. 
Geometric (Å, °) details of the intermolecular interactions: 
5 
A H B A–H H…B A…B A–H…B Symmetry 
       operation 
O3 H1o O2 0.82(3) 1.88(3) 2.699(4) 175(8) -x, ½+y, ½-z 
O3 H2o O1 0.82(4) 1.99(4) 2.807(4) 176(3) 1-x, ½+y, ½-z 
8 
O3 H1o O1 0.82(3) 2.14(3) 2.858(3) 147(3) x, ½-y, -½+z 
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 The one-dimensional coordination polymer formed in crystals of 6 packs with no specific 
atom-to-atom contacts between them; a view of unit cell contents is shown in ESI Fig. S33.  
From the image in ESI Fig. S34, it clearly apparent that there are no directional interactions 
stabilising the molecular packing in the crystal of 7.  Hydrogen bonding comes to the fore again 
in the crystal of 8; geometric parameters characterizing these are given in the caption to Figure 
3. The tin-bound water molecule functions as the donor to the more tightly bound O1 atoms to 
form a supramolecular chain along the c-axis with a zig-zag topology, being propagated by 
glide-symmetry, see Figure 3b; as shown in ESI Fig. S35, supramolecular chains assemble with 
no directional interactions between them. 
 From the foregoing, it is apparent the large adamantyl groups exert a great influence upon 
the molecular packing, primarily keeping the constituent species apart. To analyse the influence 
of the adamantyl groups further, an analysis of the molecular packing was conducted 
employing CrystalExplorer 17.0[75] and following established protocols.[76] Specifically, the 
Hirshfeld surfaces and two-dimensional fingerprint plots were calculated for 2-8 in order to 
determine the nature of the specific atom-to-atom contacts between molecules in their 
respective crystals, even though the separations are usually greater than the respective sums of 
the van der Waals radii, as indicated above with the notable exception of the structures of 5 and 
8 where hydrogen-bonding apparent. 
 The first structures to be highlighted are the triphenyltin species 2 and 6. In mononuclear 
2, H…H contacts contribute 70.1% to the overall calculated Hirshfeld surface with the next 
most prominent contacts being C…H/H…C at 24.8%; next are O…H/H…O at 4.5%. These values 
are comparable to those calculated for the repeat unit in polymeric 6, i.e. 71.6, 23.7 and 2.6% 
for H…H, C…H/H…C and O…H/H…O surface contacts, respectively. The only other contact of 
note is due to the secondary Sn…O bonding interaction, i.e. 1.5%. The calculations were then 
repeated for a six repeat-unit fragment of the polymer. In consideration of packing of the one-
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dimensional chains, the H…H surface contacts increased to 79.6%, largely at the expense of 
C…H/H…C (17.3%), O…H/H…O (1.2%) and Sn…O/O…Sn (0.0%) contacts. The only other 
structure without hydrogen-bonding potential but, with phenyl rings, giving rise to the 
possibility of C…H contacts, is hexa-nuclear 4 where H…H (86.6%), C…H/H…C (10.3%) and 
O…H/H…O (2.6%) surface contacts dominate. In tetra-nuclear 3, H…H contacts overwhelming 
dominate the calculated Hirshfeld surface, contributing 93.2%; O…H/H…O and C…H/H…C 
contacts are next at 6.1 and 0.6%, respectively. A similar situation pertains in 7, with H…H 
(88.8%) and O…H/H…O (10.8%), being the only surface contacts contributing more than 1%. 
The two remaining structures feature conventional water-O–H…O(carboxylate) hydrogen-
bonding interactions. Similar trends observed above are evident. Thus, in 5, without phenyl 
rings, the dominance of H…H (90.1%) is clear, with O…H/H…O contacts (9.1%) being the only 
other significant contributor to the Hirshfeld surface. In 8, with tin-bound benzyl substituents, 
H…H contacts fall off to 79.6% with C…H/H…C (10.4%) and O…H/H…O (10.0%) being 
approximately equal and making up the balance of surface contacts. 
 
3.4 Anti-bacterial activity results and preliminary assessment of cytotoxicity 
In order to ascertain the potential of the new organotin compounds as anti-bacterial agents, a 
variety of trials were conducted on organotin derivative 1, 2 and 5-7, pro-ligands HL1 and 
HL2 as well as the organotin precursors, i.e. Me3SnCl (S1), Ph3SnOH (S2) and Bu2SnCl2 
(S3), and standard anti-biotics Tetracycline and Chloramphenicol.  The screening protocols 
employed in the present study followed a literature precedent [77]. 
 
3.4.1. Disc diffusion screening 
The trial compounds were first screened using the Kirby-Bauer disc diffusion method with 
the results summarised in Table 2.  All compounds were evaluated as freshly prepared 
32 
 
DMSO solutions; DMSO was included in all assays as the solvent control and exhibited no 
anti-bacterial activity on any of the bacterial species.  The pro-ligands, HL1 and HL2, 
exhibited no effect against any of the panel of bacteria.  In the same way, the trimethyltin 
chloride (S1) precursor had no effect on the bacteria.  However, the precursors triphenyltin 
hydroxide (S2) and dibutyltin dichloride (S3) exhibited anti-bacterial activities on most 
species, especially on Gram-positive species having inhibition zones in the ranges 14-20 and 
11-18 mm, respectively.  Against Gram-negative bacteria, S3 was effective against all 
species, except P. aeruginosa, whereas S2 was moderately effective against a limited number 
of the species, being most potent against V. parahaemolyticus (14 mm). 
Insert Table 2 
As observed for their precursor, S1, trimethyltin derivatives, 1 and 5, demonstrated no 
anti-bacterial activity against all tested species with the exception of 5 against S. aureus 
(MRSA) (7 mm).  This observation suggests that there is no contribution to the bioactivity by 
the incorporation of the ligands L1 and L2.  By contrast and similar to their precursor S2, 
triphenyltin derivatives 2 and 6 demonstrated anti-bacterial effects against both Gram-
positive and Gram-negative bacteria.  However, as for the trimethyltin derivatives, the 
formation of triphenyltin derivatives 2 and 6 did not show improvement in their bacterial 
inhibition activity.  Compound 2 was equally effective against all tested Gram-positive 
species with inhibition zones ranging from 12-18 mm in diameter.  Notably, 2 was only 
effective against two Gram-negative bacterial species, V. parahaemolyticus (12 mm) and S. 
flexneri (7mm).  Compared to 2, 6 exerted reduced anti-bacterial activities against all Gram-
positive and was inactive against E. faecium.  Limited activity was observed against two 
Gram-negative bacterial species, i.e. P. vulgaris (10 mm) and V. parahaemolyticus (10 mm).  
Finally, 7 demonstrated similar anti-bacterial effects as for 6 but, was equal to or less potent 
than precursor S3.  Compound 7 exerted mild anti-bacterial activities against all Gram-
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positive species except E. faecium and was only effective against two Gram-negative 
bacteria, S. flexneri and V. parahaemolyticus, each with a 10 mm inhibition zone. 
The standard anti-biotics, Tetracycline and Chloramphenicol were employed (each 
with 30 µg per disc) in the experiment as positive controls.  Each anti-biotic produced 
inhibition zones ranging from 26-33 and 24-30 mm, respectively, against Gram-positive 
bacteria, and 9-25 and 11-29 mm, respectively, against Gram-negative species. 
In summary, the results from the disc diffusion anti-bacterial activity screening 
suggested that trimethyltin derivatives 1 and 5 were inactive, while 2, 6 and 7 exhibit broad 
spectrum anti-bacterial activities against both Gram-positive and Gram-negative bacteria, 
similar but, less potent that their respective precursors S2 and S3.  In comparing the potency 
of the organotin compounds with the standard anti-biotics, the former compounds are not as 
effective as the anti-biotics when same concentrations were employed in the assay. 
 
3.4.2. Determination of Minimum Inhibitory Concentration (MIC) and Minimum 
Bactericidal Concentration (MBC) 
As demonstrated in the disc diffusion assay, three of the organotin derivatives, 2, 6 and 7, and 
their respective precursors (S2 and S3), showed potential in inhibiting bacterial growth 
(Table 2).  The anti-bacterial activity of these compounds was quantitatively evaluated using 
the broth-dilution method.  The MIC and MBC values of these compounds against eight 
species, including six Gram-positive (E. faecalis, S. pyogenes, S. epidermidis, S. aureus 
(MRSA), E. faecium and S. pneumoniae) and two Gram-negative (S. flexneri and V. 
parahaemolyticus) species, was tested.  Tetracycline and Chloramphenicol were included as 
positive controls. 
In the MIC assay, striking differences are noted in the anti-bacterial potency exhibited 
by the triphenyltin species (2, 6 and S2) compared with the di-n-butyl species (7 and S3), 
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Table 3.  While the trend seen in the disc diffusion results is retained whereby the precursor 
(S3) is more potent than the dibutyltin derivative 7, neither are as potent as any of the 
triphenyltin compounds.  The precursor S2 exhibited maximum and equivalent anti-bacterial 
activity, i.e. 0.78 µg/mL, against four Gram-positive bacteria (E. faecalis, S. aureus (MRSA), 
S. epidermidis and S. pyogenes) and one Gram-negative bacterium (V. parahaemolyticus).  
Comparable activity was evident for 2 and 6 in most of Gram-negative bacteria but, not 
against the Gram-negative bacteria.  Thus, 2 and 6 each exhibited the same level of activity 
as S2, i.e. 0.78 µg/mL, against S. epidermidis and S. pyogenes; 2 was also potent against S. 
aureus (MRSA), again with a MIC value of 0.78 µg/mL.  Notably, 2 remained as the most 
effective compound among the tested organotin compound.  In summary, the MIC data 
confirmed the potent anti-bacterial activity of the triphenyltin derivatives as observed in disc 
diffusion assay. 
Insert Table 3 
After determining the anti-bacterial activities of the organotin derivatives, the 
compounds were further studied to identify their abilities either to kill (bactericidal) a 
bacterium or to inhibit the growth (bacteriostatic) of a bacterium as revealed from the 
obtained MBC/MBC ratios.  An anti-bacterial agent is considered bactericidal if the value of 
MBC is not four-fold greater than the MIC value, i.e. MBC/MIC ≤4 [78]. In the present 
study, Tetracycline demonstrated bactericidal activities against S. epidermidis and S. 
pyogenes but, was bacteriostatic towards the remaining bacteria, Table 3; Chloramphenicol 
was bactericidal towards only S. pyogenes only.  For S2, with the exception against S. 
pneumoniae, the MBC values observed in all tested species were more than 4-fold greater 
than their respective MIC values, indicating S2 to be generally bacteriostatic.  By contrast, 
the anti-bacterial activities of organotin derivatives, 2 and 6 were proven to be bactericidal 
against E. faecalis and Gram-negative V. parahaemolyticus.  The dibutyltin compound, 7, 
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while not especially potent, was able to kill both S. pneumoniae and V. parahaemolyticus 
while its precursor, S3, was only able to kill V. parahaemolyticus. 
 
3.4.3. Time-kill assay 
Following MIC and MBC determinations, time-kill assays were conducted to reveal the 
potential pharmacodynamics of the triphenyltin derivatives 2 and 6 as they were shown to be 
the most potent agents against S. pyogenes, S. epidermidis and S. aureus (MRSA), with MIC 
values of 0.78 µg/ml (Table 3).  The anti-bacterial effects of 2 and 6 were studied at various 
incubation time-points, specifically 0, 1, 2, 4, 8 and 24 h.  At all three tested concentrations 
(½ × MIC, 1 × MIC and 2 × MIC), 2 was able to suppress the growth of S. pyogenes for 8 h, 
followed by a spike in growth with the exception of bacteria treated with 2 × MIC, Fig. 4a.  A 
similar response was noted against S. epidermidis except growth of the 2 × MIC-treated 
bacterium after 8 h, Fig. 4b.  For S. aureus (MRSA), the growth was inhibited for 8 h at MIC 





Fig. 4.  Time-kill curves for 2 against (a) S. pyogenes, (b) S. epidermidis and (c) S. aureus 
(MRSA).  The bactericidal level is indicated by the dashed line , negative control ●, ½ × 
MIC ▲, 1 × MIC ♦ and 2 × MIC ×. 
 
To a first approximation, 6 gave similar time-kill responses as for 2 against both S. 
pyogenes and S. epidermidis.  Against, S. pyogenes, Figure 5a, and S. epidermidis, Fig. 5b, 
growth was maintained for 4 h at ½ × MIC and two additional hours at both MIC and 2 × 
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MIC.  A summary of the bacterial count numbers at different concentrations and time-points 
is presented in Table 4. 
 
 
Fig. 5.  Time-kill curves for 6 against (a) S.  pyogenes and (b) S. epidermidis.  The 
bactericidal level is indicated by the dashed line , negative control ●, ½ × MIC ▲, 1 × 
MIC ♦ and 2 × MIC ×. 
 
Typically, anti-biotics are classified into two classes, those that are bactericidal, i.e. 
able to kill bacteria, and those that are bacteriostatic, i.e. able to inhibit bacterial growth.  
Conventionally, bactericidal anti-biotics are preferred for patients who are severely ill or 
immunosuppressed, as reflected in the guidelines for anti-biotic use [79]. The present results 
showed that the anti-bacterial activity of 2 and 6 was bacteriostatic towards the bacterial 
species tested.  Although having bactericidal activity might be thought desirable, a systematic 
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review and meta-analysis conducted in 2014 suggested that the categorisation of 
bacteriostatic and bactericidal anti-biotics is most likely irrelevant in clinical practice as there 
was no correlation between the use of bactericidal agents and clinical cure rates and mortality 
rates [80]. In summary, the anti-bacterial effects of 2, 6, 7, S2 and S3 were broad spectrum, 
targeting both Gram-positive and Gram-negative bacteria.  Based on time-kill studies, 2 and 6 
exhibited bacteriostatic effects on selected bacteria tested. 
Insert Table 4 
 
3.4.4. Cytotoxicity assay 
As a preliminary evaluation of the toxicity of the compounds towards mammalian cells, 
cytotoxicity screening was conducted on a representative cell line, HEK293T, i.e. a human 
embryonic kidney cell line, using the MTT proliferation assay.  All test compounds exhibited 
dose-dependent cytotoxic effects with the results summarised in Table 5; graphs are 
presented in ESI Fig. S36.  The pro-ligands HL1 and HL2 were non-cytotoxic, maintaining 
>80% cell viability at 100 µg/mL.  However, the organotin derivatives and precursors 
exhibited cytotoxic effects, with log10(CC50) values ranging from 0.079 to 1.579 µg/mL.  The 
trimethyltin derivatives, 1 and 5, were least toxic to normal cells.  By contrast, the potent 
anti-bacterial agents 2 and 6 were cytotoxic towards HEK293T, demonstrating low 
log10(CC50) values of 0.079 ± 0.035 and 0.084 ± 0.046 µg/mL, respectively.  The dibutyltin 
dichloride precursor, S3, was the most cytotoxic to HEK293T among the tested compounds 
but, 7 was less so, i.e. log10(CC50) = 0.421 ± 0.045 µg/mL. 
 





3.4.5. Overview of anti-bacterial assays 
Described as a “lipophilic bullet” in their seminal review of the pharmacological potential of 
adamantane derivatives, being second only to methyl in its impact, Wanka and Schreiner 
highlighted the potential of appending adamantane-containing molecules to already active 
pharmaceutical ingredients (API’s) to enhance their therapeutic value [5].  The anti-bacterial 
activity of organotin derivatives, including organotin carboxylates, is already well-
documented [33] so it seemed a natural step forward to evaluate the anti-bacterial potential of 
a variety of organotin species coupled with adamantane carboxylates.  Further, broad-
spectrum anti-bacterial behaviour exhibited by adamantane-1-carbohydrazides in contrast to 
limited anti-fungal activity was ascribed to the lipophilic attributes of the molecules [81].  
Previous mechanistic studies highlighted the important role of lipophilic agents to interact 
and penetrate into the phospholipid membrane of bacteria hence, disrupting the membrane 
structure and crucial biological functions essential for cell survival [82]. 
Based on the new results, triphenyltin compounds such as 2 and 6 are better anti-
bacterial agents compared to trimethyltin compounds (1 and 5), regardless of the specific 
ligand employed.  Dibutyltin derivative, 7, demonstrated moderate anti-bacterial activity.  It 
has been reported that the organotin derivatives containing phenyl substituents generally 
exert better anti-bacterial activity compared to compounds with methyl and butyl substituents 
[83].  The enhanced anti-bacterial activity for the triphenyltin derivatives may be attributed to 
an increase in the lipophilicity of these compounds which may facilitate their entry into the 
lipid bilayer of bacterial cell membrane before exerting the observed anti-bacterial effects. 
The results showed that some of the organotin compounds were as effective as 
commercially available anti-biotics.  When the anti-bacterial activity of the new organotin 
compounds was screened using disc diffusion assays, they appeared to be less effective in 
terms of their anti-microbial activity compared with both tetracycline and chloramphenicol.  
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However, when tested using the broth dilution method, the gold standard method for anti-
microbial screening assay, the MIC results showed that although the potent anti-bacterial 
agent tetracycline consistently out-performed each of 2, 6 and 7, triphenyltin compounds 2 
and 6 had lower MIC values on Gram-positive bacteria including E. faecium, MRSA, S. 
epidermidis, S. pyogenes and S. pneumoniae compared to chloramphenicol, indicating that 2 
and 6 are potentially novel anti-bacterial agents for these pathogens.  Existing anti-biotics 
such as chloramphenicol are losing their effectiveness in certain bacteria, for instance, MRSA.  
The development of organotin compounds, such as 2 and 6, presents new alternatives to 
infectious diseases caused by multi-drug resistant bacteria. 
 
4. Conclusion 
A series of nine diamondoid-decorated organotin(IV) derivatives were prepared by reacting two 
adamantyl carboxylic acids, or their sodium salts, with tin precursors containing various organic 
groups. FT-IR and 1H NMR confirmed Sn–O bond formation between the carboxylate group of 
the ligand and the organotin moiety. X-ray crystallography and 119Sn NMR indicated the hexa-
coordinate drum structure of the monoorganostannoxanes [BzSn(O)(L1)]6 (4) and the structure 
[BzSn(O)(L2)]6 (9) are retained in solution, whereas the solid-state five-coordinate monomer or 
polymeric structures of  triganostannoxanes Me3Sn(L1) (1), Ph3Sn(L1) (2), Me3Sn(L2)OH2 (5) and 
[Ph3Sn(L2)]n (6) are four-coordinate in solution. The diorganostannoxes {[Me2Sn(L1)]2O}2 (3) 
and Bu2Sn(L2)2 (7) form ladder and trapezoidal bipyramid structure, respectively, that are 
retained in solution, while Bz2Sn(L2)2OH2 (8) probably dissociates water in solution to give a 
hexa-coordinate species. The presence of water in compounds 5 and 8 results in hydrogen 
bonding, giving rise to supramolecular layer with a zig-zag topology (5) and a zig-zag chain (8). 
The anti-bacterial effects of selected organotin compounds showed that the triphenyltin 
derivatives 2 and 6 exhibited promising broad-spectrum, anti-bacterial effects with maximum 
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potency towards S. pyogenes, S. epidermidis (2 and 6) and S. aureus (MRSA) (2).  Time-kill 
assays proved 2 and 6 to be bacteriostatic against these bacteria.  Despite being cytotoxic towards 
normal cells, the new results suggest further studies in this area are warranted. 
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Table 1  
Crystal data and refinement details for compounds 2-8. 
Compound 2 3 4 5 6 
Formula C29H30O2Sn C52H84O10Sn4 C108H132O18Sn6 C15H28O3Sn C30H32O2Sn 
Formula weight 529.22 1343.95 2430.26 375.06 543.24 
Crystal colour Colourless Colourless Colourless Colourless Colourless 
Crystal size/mm3 0.18 × 0.29 × 0.40 0.29 × 0.34 × 0.34 0.09 × 0.09 × 0.12 0.21 × 0.23 × 0.25 0.21 × 0.23 × 0.25 
Crystal system Triclinic Triclinic Triclinic Monoclinic Monoclinic 
Space group P1̄ P1̄ P1̄ P21/c P21/c 
a/Å 10.6294(5) 10.7891(4) 10.9275(8) 6.7994(6) 11.8587(5) 
b/Å 11.2196(6) 11.2192(4) 16.1173(9) 10.9676(10) 19.4239(8) 
c/Å 11.2956(5) 12.7586(5) 16.4920(11) 22.657(3) 11.0727(4) 
α/° 77.523(4) 97.827(3) 67.873(6) 90 90 
β/° 72.559(4) 99.853(3) 76.821(6) 95.782(9) 97.887(4) 
γ/° 79.975(4) 113.286(3) 75.605(6) 90 90 
V/Å3 1246.13(11) 1361.73(9) 2576.8(3) 1681.0(3) 2526.38(18) 
Z 2 1 1 4 4 
Dc/g cm-3 1.410 1.639 1.566 1.482 1.428 
F(000) 540 676 1224 768 1112 
µ(MoKα)/mm-1 1.048 1.866 1.497 1.522 1.035 
Measured data 9105 10319 20708 6605 10007 
θ range/° 3.2 – 28.7 3.3 – 28.7 2.9 – 28.8 3.3 – 29.1 3.6 – 29.0 
Unique data 5561 6165 11632 3815 5759 
Observed data (I ≥ 2.0σ(I)) 4940 5340 8890 3332 4625 
No. parameters 289 302 595 182 298 
R, obs. data; all data 0.031; 0.083 0.023; 0.057 0.039; 0.077 0.038; 0.103 0.042; 0.082 
a; b in weighting scheme 0.051; 0.367 0.031; 0.800 0.032; 0.841 0.061; 1.298 0.033; 0.590 
Rw, obs. data; all data 0.037; 0.088 0.030; 0.062 0.062; 0.087 0.047; 0.107 0.058; 0.089 
Range of residual electron 




Compound 7 8 
Formula C32H52O4Sn C38H50O5Sn 
Formula weight 619.45 705.47 
Crystal colour Colourless Colourless 
Crystal size/mm3 0.51 × 0.56 × 0.59 0.15 × 0.19 × 0.25 
Crystal system Monoclinic Orthorhombic 
Space group C2/c Pccn 
a/Å 19.8489(17) 12.8110(6) 
b/Å 7.1831(5) 19.3164(10) 
c/Å 23.0559(16) 13.2171(5) 
α/° 90 90 
β/° 109.019(9) 90 
γ/° 90 90 
V/Å3 3107.8(4) 3270.7(3) 
Z 4 4 
Dc/g cm-3 1.324 1.433 
F(000) 1304 1468 
µ(MoKα)/mm-1 0.855 0.824 
Measured data 5936 8687 
θ range/° 3.3 – 29.0 3.1 – 29.0 
Unique data 3503 3795 
Observed data (I ≥ 2.0σ(I)) 3089 2775 
No. parameters 169 203 
R, obs. data; all data 0.044; 0.099 0.039; 0.082 
a; b in weighting scheme 0.052; 0.602 0.038; 0.567 
Rw, obs. data; all data 0.053; 0.104 0.060; 0.092 
Range of residual electron  




 Anti-bacterial activity of organotin compounds (1, 2, 5-7), precursors (S1-S3), pro-ligands (HL1 and HL2) and standard 





















a A zone of inhibition was not detected.  All experiments were performed in triplicate.  The smallest zone of inhibition 
(mm) recorded in the three independent studies is presented in this Table. 
Bacterial species 1 2 5 6 7 S1 S2 S3 L1 L2 Tetracycline Chloramphenicol 
Gram-positive bacteria             
E. faecalis  - 16 - 10 10 - 16 16 - - 30 30 
S. pyogenes  - 18 - 11 11 - 20 18 - - 26 29 
S. epidermidis  - 18 - 13 13 - 19 18 - - 30 30 
S. aureus (MRSA)  - 17 7 8 8 - 18 14 - - 27 24 
E. faecium  - 17 - - - - 14 11 - - 27 24 
L. monocytogenes  - 12 - 9 9 - 15 15 - - 27 24 
S. penumoniae  - 15 - 9 9 - 19 17 - - 33 30 
             
Gram-negative bacteria             
K. pneumoniae  - - - - - - 8 14 - - 24 26 
K. quasipneumoniae  - - - - - - - 9 - - 24 26 
P. aeruginosa  - - - - - - - - - - 10 11 
S. enterica 8 - - - - - - - 10 - - 16 25 
E. coli ATCC 11775 - - - - - - - 9 - - 20 25 
E. coli K1 - - - - - - 8 7 - - 23 26 
S. flexneri  - 7 - - 10 - 7 12 - - 25 29 
P. vulgaris  - - - 10 - - 7 10 - - 9 17 





MIC (μg/mL) and MBC/MIC ratio for organotin compounds (2, 6 and 7), precursors (S2 and S3) and standard anti-biotics 
(Tetracycline and Chloramphenicol) against eight pathogenic bacteriaa-c 
 
a MIC-minimum inhibitory concentration (μg/mL); MBC: minimum bactericidal concentration (μg/mL); MBC/MIC ratio ≤ 4 
indicates bactericidal activity; MBC/MIC ratio >4 indicates a bacteriostatic activity; ND – MBC/MIC could not be determined as 
bacterium had grown across all tested concentrations, with MBC >100 µg/mL. 
 
b The presented MIC values are the lowest inhibitory concentrations obtained from three independent experiments conducted in 
triplicate. 
 
c HL1 and HL2 did not show anti-bacterial activity as bacterial cells grew at all concentrations tested (0.78 – 100 µg/mL), hence 
data are not presented in the table. 
Bacterial Species 2 6 7 S2 S3 Tetracycline Chloramphenicol 
  MIC MBC/MIC MIC MBC/MIC MIC MBC/MIC MIC MBC/MIC MIC MBC/MIC MIC MBC/MIC MIC MBC/MIC 
E. faecalis 3.125 4 3.125 4 25 ND 0.78 8 3.125 ND 0.198 32 3.125 ND 
E. faecium 1.56 16 3.125 8 50 ND 1.56 8 25 ND 0.198 253 6.25 ND 
S. aureus (MRSA) 0.78 32 1.56 16 25 ND 0.78 16 6.25 ND 0.39 128 12.5 ND 
S. epidermidis 0.78 16 0.78 16 12.5 8 0.78 16 1.56 16 0.198 2 3.125 8 
S. pneumoniae 1.56 8 1.56 8 25 4 1.56 4 6.25 8 0.39 8 6.25 16 
S. pyogenes 0.78 16 0.78 16 12.5 ND 0.78 16 3.125 8 0.198 4 3.125 4 
S. flexneri 12.5 ND 12.5 ND 25 ND 6.25 ND 3.125 ND 1.56 32 1.56 ND 




Table 4  
Summary of in vitro time-kill study of organotin compounds 2 and 6 on S. pyogenes, S. epidermidis and S. Aureus 
(MRSA). 
Bacterial species Complex Log10 CFU/mLa 
  1/2 × MIC 1 × MIC 2 × MIC 
  1 h 2 h 4 h 8 h 24 h 1 h 2 h 4 h 8 h 24 h 1 h 2 h 4 h 8 h 24 h 
S. pyogenes 2 0.08 0.02 0.25 0.59 4.89 -0.03 -0.04 0.13 0.27 1.71 0.04 -0.07 -0.04 -0.28 -0.83 
 6 0.01 0.24 0.35 1.37 4.98 0.03 0.21 0.33 0.47 1.79 0.06 0.17 0.17 0.08 0.96 
S. epidermidis 2 0.01 0.07 0.25 0.54 4.18 -0.01 -0.04 0.11 0.11 1.56 0.04 -0.02 0 -0.62 1.18 
 6 -0.01 0.05 0.31 1.24 6.12 0.01 0.00 0.16 0.32 1.75 0.02 0.00 0.03 -0.027 1.84 
S. Aureus (MRSA) 2 0.09 0.27 1.27 2.41 4.53 0.01 -0.01 -0.03 0.16 4.26 0.06 0.03 0.00 0.05 3.67 
a Values are the mean of values obtained from three independent biological replicates, each biological replicate 
comprised three technical replicates; a negative value indicates a reduction in bacterial number whereas a positive 




Cytotoxicity of organotin compounds (1, 2 and 5-7), precursors (S1-S3), pro-ligands 










 The log10(CC50) (µg/mL) value indicates the cytotoxic concentration at which a 
compound is able to kill 50% the original human cell population seeded in a well of a 
96-well plate. 
Compounds log10[CC50 ± 
SE] (µg/mL) 
Controls log10[CC50 ± SE] 
(µg/mL) 
1 1.390 ± 0.148 S1 1.009 ± 0.114 
2 0.079 ± 0.035 S2 -0.046 ± 0.028 
5 1.579 ± 0.166 S3 -0.141 ± 0.064 
6 0.084 ± 0.046 HL1 >2 
7 0.421 ± 0.045 HL2 >2 
55 
 
Legends to Scheme and Figures 
Scheme 1. Synthetic methodologies used for obtaining organotin(IV) compounds 1-9. The 
numbers at the pro-ligands (HL1 and HL2) denote the atom-numbering protocol used for the 
NMR signal assignment. 
 
Fig 1. The molecular structures of (a) Ph3Sn(L1) 2 (25% probability level), (b) {[Me2Sn(L1)]2O}2 
3 (50% probability level) and (c) [BzSn(O)(L1)]6 4 (25% probability level), showing the atom 
labelling schemes and anisotropic displacement parameters. The unlabelled atoms are related by 
the symmetry operation 2-x, 2-y, 2-z (3) and 2-x, 1-y, -z (4). 
In 3, the carbon atoms are indicated by numbers only to reduce cluttering. Selected geometric 
parameters for the bridging carboxylate ligands in 3: Sn1–O4 = 2.141(3), Sn2–O5 = 2.140(3), 
C1–O4 = 1.260(5), C1–O5 = 1.252(5), Sn1–O6 = 2.167(3), Sn3–O7 = 2.139(3), C12–O6 = 
1.257(5), C12–O7 = 1.266(5), Sn3–O8 = 2.140(3), Sn2–O9i = 2.138(3), C23–O8 = 1.264(5), 
C23–O9 = 1.259(4) Å. 
 
Fig 2.  The molecular structures of (a) Me3Sn(L2)OH2 5 (25% probability level), (b) [Ph3Sn(L2)]n 
6 (25% probability level; the arrows indicate the links to generate the supramolecular, one-
dimensional coordination polymer shown in (c)), (d) Bu2Sn(L2)2 7 (25% probability level) and 
(e) Bz2Sn(L2)2OH2 8 (35% probability level), showing the atom labelling schemes and 
anisotropic displacement parameters. The unlabelled atoms are related by the symmetry 




Fig 3.  Molecular packing sustained by hydrogen bonding in the crystals of 5 and 8: (a) 5, a view 
of the supramolecular layer in the ab-plane sustained by water-O–H…O(carboxylate) hydrogen 
bonding and (b) a view of the zig-zag supramolecular chain along the c-axis sustained water-O–
H…O(carboxylate) hydrogen bonding.  Non-participating hydrogen atoms have been omitted for 
reasons of clarity. 
Geometric (Å, °) details of the intermolecular interactions: 
5 
A H B A–H H…B A…B A–H…B Symmetry 
       operation 
O3 H1o O2 0.82(3) 1.88(3) 2.699(4) 175(8) -x, ½+y, ½-z 
O3 H2o O1 0.82(4) 1.99(4) 2.807(4) 176(3) 1-x, ½+y, ½-z 
8 
O3 H1o O1 0.82(3) 2.14(3) 2.858(3) 147(3) x, ½-y, -½+z 
 
Fig 4.   Time-kill curves for 2 against (a) S. pyogenes, (b) S. epidermidis and (c) S. aureus 
(MRSA).  The bactericidal level is indicated by the dashed line , negative control ●, ½ × MIC 
▲, 1 × MIC ♦ and 2 × MIC ×. 
 
 
Fig 5. Time-kill curves for 6 against (a) S.  pyogenes and (b) S. epidermidis.  The bactericidal 
level is indicated by the dashed line , negative control ●, ½ × MIC ▲, 1 × MIC ♦ and 2 × 
MIC ×. 
 
 
